Clincosm LogoSign in Get a demo

Scintigraphic Assessment of I- Transport in Metastatic Breast Cancer and Evaluation of I31I Ablative Therapy: (Part I) Radioiodide Imaging Study

Sponsor
Stanford University (Other)
Overall Status
Completed
CT.gov ID
NCT00185809
Collaborator
Susan G. Komen Breast Cancer Foundation (Other)
25
Enrollment
1
Location
93
Duration (Months)
0.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to examine breast cancers that express the protein (NIS) that may be found in malignant breast tissues and to evaluate proteins found in blood and their relationship to NIS, to test whether iodide can be concentrated by breast cells to possibly treat some breast cancers with radioactive iodine, and to calculate the amount of radioactive iodine entering breast cancer cells, how long your cancer retains the agent as well as how much is taken up by other organs, particularly the thyroid gland.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    To demonstrate iodide uptake capacity of breast cancer metastases by imaging women with iodide radioisotope (123I) and calculating potential ablative dose of radioactive iodide (131I).

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    25 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Scintigraphic Assessment of I- Transport in Metastatic Breast Cancer and Evaluation of I31I Ablative Therapy: (Part I) Radioiodide Imaging Study
    Study Start Date :
    Nov 1, 2000
    Actual Primary Completion Date :
    Aug 1, 2008
    Actual Study Completion Date :
    Aug 1, 2008

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      18 Years to 70 Years
      Sexes Eligible for Study:
      Female
      Accepts Healthy Volunteers:
      No

      Inclusion Criteria:- Only women diagnosed with breast cancer

      • 18 years of age or older

      • From whom informed consent can be obtained

      • Patient is able to provide a fluid (e.g. cyst fluid)

      • Patient with blood test that shows protein may allow iodide to accumulate in breast tissue

      • Patient who's breast cancer cells accumulated I123 and held on to it for 24 hours Exclusion Criteria:- Males

      • Children

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 Stanford University School of Medicine Stanford California United States 94305

      Sponsors and Collaborators

      • Stanford University
      • Susan G. Komen Breast Cancer Foundation

      Investigators

      • Principal Investigator: Irene L. Wapnir, Stanford University

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      None provided.
      Responsible Party:
      , ,
      ClinicalTrials.gov Identifier:
      NCT00185809
      Other Study ID Numbers:
      • BRSMTS0002
      • 75632
      • BRSMTS0002
      • NIH
      First Posted:
      Sep 16, 2005
      Last Update Posted:
      Jul 20, 2010
      Last Verified:
      Jul 1, 2010
      Additional relevant MeSH terms:
      Breast Neoplasms

      Study Results

      No Results Posted as of Jul 20, 2010